Melatonin treatment

ApprovedSmall molecule

FFederal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health

Melatonin treatment is one of 28 small molecule programs targeting Ischemic stroke. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ischemic StrokeActive, not recruiting

Ischemic StrokeApproved

Active, not recruiting

Competition

Competitive Landscape

430 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Melatonin treatment

FFederal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health

Approved

1 2

Repatha

Amgen

Preclinical

2 3

Levaquin

WWim Janssens

Preclinical

3 4

Tylenol

KKenvue Brands

Preclinical

1 5

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 6

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

1 7

Statins

Sanofi

Preclinical

1 8

Urokinase

Mmedac GmbH

Preclinical

3 9

Drug Therapy

MMassachusetts General Hospital

Preclinical

1 10

Ginkgo Biloba Extract

NNational Center for Complementary and Integrative Health (NCCIH)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Ischemic Stroke

NCT05247125

Clinical

Trials by Indication[1]

Ischemic stroke1 trial

The Role of Circadian Factors in Regulation of Neuroplasticity in Ischemic Stroke (Interventional)

Recruiting·FFederal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health·Phase 4·NCT05247125·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Melatonin treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Melatonin treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Melatonin treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: FFederal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health

Melatonin treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Ischemic stroke1 trial

References

Drug Info

Quick Facts

Related News